I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in tech and innovation within the healthcare industry. Ivan has dedicated much of his career to advancing research and development, particularly in the intersection of technology and organ
In a landscape where patients with relapsed or refractory T-cell lymphoma face a grim prognosis, often with a median survival of just six months under current treatments, a new ray of hope has emerged through innovative research. This aggressive cancer, marked by limited therapeutic options, has
In an era where global tensions and unexpected crises are becoming commonplace, the pharmaceutical industry faces unprecedented challenges in conducting clinical trials, which are essential for bringing life-saving drugs to market, and geopolitical instability—whether through armed conflicts like
Could a single enzyme hold the key to transforming outcomes for one of the deadliest cancers known to medicine? Pancreatic cancer, with its dismal survival rates and relentless spread, claims countless lives each year, often leaving patients and families with little hope. Yet, a groundbreaking
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research and development, paired with a passion for technology and innovation, has positioned him at the forefront of transformative advancements in the industry. Today, we’ll dive into the
In a significant stride toward combating advanced lung cancer, the U.S. Food and Drug Administration has granted Fast Track designation to a promising new therapy known as AVZO-1418, also referred to as DB-1418. This innovative treatment targets patients with unresectable, locally advanced, or
